Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Neonc Technologies, Inc.
xCures
Var2 Pharmaceuticals
Degron Therapeutics Co.
Massive Bio, Inc.
LigaChem Biosciences, Inc.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Apollomics Inc.